The findings pave the way for the development of new therapeutic strategies combining immunotherapy with p38α protein inhibitors. A study…
VHIR
Under the agreement, IQVIA will preferentially offer Vall d’Hebron clinical studies managed by the company. Vall d’Hebron Barcelona Hospital Campus…
The Vall d’Hebron Barcelona Hospital Campus and Biocat held a new session of the ATMP Catalonia Series, titled ‘ATMPs: From…
